ReviewTherapeutic advances in drug safety2010
Drug-induced liver injury in older adults.
Review in Therapeutic advances in drug safety, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- The impact of aging on liver health and the development of liver diseases.Hepatology communications · 2025Review
- Multiscale modeling of drug-induced liver injury from organ to lobule.NPJ digital medicine · 2025Article
- Phenoconversion andHepatology forum · 2025Review
- The multiple mechanisms and modes of cell death after acetaminophen overdose.Exploration of digestive diseases · 2025Article
- A virtual scalable model of the Hepatic Lobule for acetaminophen hepatotoxicity prediction.NPJ digital medicine · 2024Article
- Moderate Alcohol Consumption Increases the Risk of Clinical Relapse in Male Depressed Patients Treated with Serotonin-Norepinephrine Reuptake Inhibitors.Diagnostics (Basel, Switzerland) · 2024Article
- Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative.Drug safety · 2024Article
- Turmeric-induced Liver Injury.Journal of community hospital internal medicine perspectives · 2024Article
- Chronic Liver Disease in the Older Patient-Evaluation and Management.Current gastroenterology reports · 2023Review
- An original donor-dependent spheroid system for the prediction of idiosyncratic drug-induced liver injury risk.In vitro models · 2023Article
- Mitochondria as the Target of Hepatotoxicity and Drug-Induced Liver Injury: Molecular Mechanisms and Detection Methods.International journal of molecular sciences · 2022Review
- Age-Associated Risk of Liver-Related Adverse Drug Reactions.Frontiers in medicine · 2022Article
- Epigallocatechin-3-gallate Mo nanoparticles (EGM NPs) efficiently treat liver injury by strongly reducing oxidative stress, inflammation and endoplasmic reticulum stress.Frontiers in pharmacology · 2022Article
- Evaluation of Adverse Drug Reactions in Paediatric Patients: A Retrospective Study in Turkish Hospital.Frontiers in pharmacology · 2021Article
- Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury.International journal of molecular sciences · 2016Review
- Drug-Induced Liver Toxicity and Prevention by Herbal Antioxidants: An Overview.Frontiers in physiology · 2015Review
- TITLE Disposition and kinetics of Tetrabromobisphenol A in female Wistar Han rats.Toxicology reports · 2014Article
- Age-related changes in the hepatic pharmacology and toxicology of paracetamol.Current gerontology and geriatrics research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced liver injury (DILI) is an important cause of hospitalisation and of medication deregistration. In old age, susceptibility to DILI is affected by changes in physiology and increased interindividual variability, compounded by an increased prevalence of disease and the frailty syndrome. While dose-related or predictable DILI reactions are often detected in preclinical trials, the occurrence of rare hypersensitivity or idiosyncratic reactions cannot be reliably predicted from preclinical studies or even by clinical trials. The limited participation of older adults in clinical trials means that the susceptibility of this population to DILI is largely unknown. Vigilance during clinical trials and postmarketing surveillance must be universally practised. A systematic approach should be taken to determine not only which medicines are hepatotoxic and should be removed from the market, but also the hepatotoxicity risks from marketed drugs to consumers with different characteristics, many of whom are older people.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.